9/20/2023 0 Comments Silverback therapeutics layoffsActual performance may differ significantly from backtested performance. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. ![]() Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. ![]() The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. It is not intended as legal advice and should not be relied upon.Disclaimer: The TipRanks Smart Score performance is based on backtested results. The information is provided as a public service. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. (NASDAQ: SBTX) have certain options and should contact the Shareholders Foundation. ![]() Those who purchased shares of Silverback Therapeutics, Inc. (NASDAQ: SBTX) declined to as low as $10.80 per share on September 23, 2021. is now available on the ESMO website." Per the abstract, while there was a manageable safety profile for the Company's experimental therapy, the best overall response was PR (n=1), SD (n=3), and PD (n=10). issued a press release "announc that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021" and advising that "he accepted abstract. Then, on September 13, 2021, Silverback Therapeutics, Inc. conducted its initial public offering ("IPO"), offering 11.5 million shares of common stock priced at $21.00. On or around December 3, 2020, Silverback Therapeutics, Inc. Seattle, WA based Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |